Sign in
Taking peopleNo phase

Building prediction models for moderate to severe thyroid eye disease

Develops models to predict moderate to severe thyroid-associated ophthalmopathy in adults.

Key facts

Who runs it
Shanghai Changzheng Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
Status
Recruiting
People taking part
150 people, planned
Started
9 Oct 2024
Expected to end
6 Sept 2028
Type of study
Observational
Record updated
24 June 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • According to the Bartley criteria,diagnosed TAO at our hospital after 2024/8/31
  • Moderate to severe patients defined by EUGOGO
  • CAS ≥3 (on the 7-item scale) for the study eye

Who cannot take part

  • History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \>1 g of methylprednisolone for the treatment of TAO
  • Any major illness/condition or evidence of an unstable clinical condition that, in the investigator\'s judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
  • Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant\'s participation in the study
  • Any other condition that,would impair the ability of the participant to undergo orbital MRI
  • Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
  • Pregnant or lactating
  • Incomplete information

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.

Read full original descriptionShow less

The aim of this clinical study is to:

1. Found the new diagnostic markers or imaging sequences. 2. Establish and validate a multimodal and multiparameter prediction model for moderate to severe TAO.

The group in the trial

  • TAO

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy
Plain-language title
Building prediction models for moderate to severe thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
Fit questions
Built from NCT06590220, who can take part
Record updated
24 June 2025